Showing results (61-70 of 223) with videos related to
Sort By:
Pageof 23
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|April 1, 2018
[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]José Palacios Calvo, Joan Albanell, Federico Rojo, et al.Current Medicinal Chemistry|December 21, 2016
Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer ModelsPaula Gonzalez-Alonso, Ion Cristobal, Sandra Zazo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancerJosé Baselga, Joan Albanell, Amparo Ruiz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitionJoan Albanell, Federico Rojo, Steve Averbuch, et al.Neoplasia (New York, N.Y.)|May 19, 2026
Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancerMelani Luque, Miriam Morales-Gallego, Marta Sanz-Álvarez, et al.Cancers|May 27, 2026
Centralized Homologous Recombination Repair Testing in Metastatic Castration-Resistant Prostate Cancer: Real-World Data from a Multicenter Spanish Precision Oncology ProgramBelén Caramelo, Pilar García-Berbel, Sofia Del Carmen, et al.International Journal of Molecular Sciences|January 11, 2024
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell LinesMarta Sanz-Álvarez, Melani Luque, Miriam Morales-Gallego, et al.Journal of the National Cancer Institute|April 19, 2007
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerMaurizio Scaltriti, Federico Rojo, Alberto Ocaña, et al.Cancers|December 23, 2022
Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast CancerMelani Luque, Marta Sanz-Álvarez, Miriam Morales-Gallego, et al.International Journal of Molecular Sciences|November 11, 2022
Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT PathwayBirlipta Pattanayak, Ana Lameirinhas, Sandra Torres-Ruiz, et al.Pageof 23